Immuneering Corporation (IMRX) Free cash flow 2020–2025
Immuneering Corporation (IMRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$45.5MFY2025 · since FY2020: -$14.7M → -$45.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$45.5M | +17.4% |
| FY2024 | -$55.1M | -11.7% |
| FY2023 | -$49.3M | -10.0% |
| FY2022 | -$44.8M | -45.1% |
| FY2021 | -$30.9M | -110.7% |
| FY2020 | -$14.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Gross marginIMRX Operating incomeIMRX Operating marginIMRX Operating cash flowIMRX Capital expendituresIMRX Return on equityIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Total liabilitiesIMRX Shareholders’ equityIMRX overview →